Content
Important Economic And Geopolitical Questions - And Their Answers
Article By:
Raymond Matison
Read
Wednesday, May 15, 2024 4:25 AM EDT
Determining America’s economic trends and world leadership position is no longer difficult; all we need to do is answer some simple but foundational questions.
Q1 2024 U.S. Retail Preview: Sales Picked Up
Article By:
Lipper Alpha Insight
Read
Tuesday, May 14, 2024 5:43 PM EDT
Leisure Products is facing difficult comparisons and has the weakest anticipated Q1 2024 estimate, with profits expected to decline by -13.8%.
In this article: XRT
Organigram Q2 Financial Metrics Mixed
Article By:
Lorimer Wilson
Read
Tuesday, May 14, 2024 2:00 PM EDT
Of the top 3 licensed producers in Canada Organigram is the only one with significant cash, negligible debt, and sizeable funds earmarked for strategic international investment.
In this article: OGI
Fixed Income ETFs Record Largest Inflow In Over Five Years, Adding $9.4 Billion
Article By:
Lipper Alpha Insight
Read
Tuesday, May 14, 2024 12:49 PM EDT
During the fund-flows week, investors were overall net purchasers of fund assets (including both conventional funds and ETFs) for the third straight week, adding a net $36.4 billion.
QNST: Auto Insurance Ramp Up Gaining Momentum, Increase Target Price To $20.00
Article By:
Robert Maltbie
Read
Tuesday, May 14, 2024 11:10 AM EDT
QuinStreet Inc. specializes in performance marketing products and technologies.
In this article: QNST
Current Analysis: Sweden-Based, Elekta AB
Article By:
Fredrik Arnold
Read
Monday, May 13, 2024 9:50 PM EDT
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. Over the past year, Elekta's share price fell about 9.4%.
In this article: EKTAF
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Article By:
Lorimer Wilson
Read
Monday, May 13, 2024 1:37 PM EDT
This article highlights the performance last week of the 10 clinical-stage AI-powered and psychedelic compound-based drug discovery companies in the munKNEE Clinical-Stage BioTech Drug Stocks Portfolio,
USD/JPY Forecast: One Way Trade
Article By:
Christopher Lewis
Read
Monday, May 13, 2024 8:11 AM EDT
The shooting star from the Thursday candlestick of course is a very negative turn of events and if we were to break above the top of that shooting star, then it allows the US dollar to go much higher.
Warner Bros. Discovery Posts $9.96 Billion In Q1 Revenues, Missing Estimates Amid Strategic Shifts
Article By:
ValueWalk
Read
Monday, May 13, 2024 7:56 AM EDT
WB Discovery had a number of challenges in the first quarter and failed to meet its anticipated sales and earnings targets. The company announced a $0.40 per share loss on $9.96 billion in revenues, which was less than the predicted $10.231 billion.
In this article: WBD
Dax Forecast: Continues To Climb
Article By:
Christopher Lewis
Read
Monday, May 13, 2024 7:44 AM EDT
The DAX has been rather bullish for some time now and it took off again during the trading session on Friday.
It looks like the 18,800 euro level is giving a little bit of resistance, but this is a market that you have no business being short of.
In this article: DAX
Stocks Momentum Largely Improved After Evidences Show Fed Turns Into Dovish
Article By:
Fullerton Markets
Read
Monday, May 13, 2024 7:12 AM EDT
Investors have been more optimistic lately after the Fed indicated the next move is unlikely to be a hike, pointing to a cap on interest rates that could be bullish for equities
The German Index Has Hit An All-Time High
Article By:
JustMarkets
Read
Monday, May 13, 2024 6:30 AM EDT
The DAX index gained nearly 0.5% on Friday to close at a record high of 18,773, extending its weekly gain to 4.3% as investors remain optimistic that major central banks will soon begin cutting interest rates.
Poor Consumer Confidence Is A Consequence Of The Wrong Policies
Article By:
Daniel Lacalle
Read
Monday, May 13, 2024 6:15 AM EDT
Rising costs of living, higher taxes, and higher inflation are the reasons why Americans have a negative perception of an allegedly strong economy.